PMC

The proportions of patients in the AMPLE study meeting ACR20, -50, and -70 responses over 1 year for the ITT population (n = 318 in the s.c. abatacept group, n = 328 in the adalimumab group). []. Copyright © 2013 by the American College of Rheumatology.
AMPLE is an ongoing study comparing s.c. abatacept vs adalimumab in biologic-naïve patients with background MTX. Error bars represent 95% CI.

Cumulative probability plot showing the distribution of change in van der Heijde modified total Sharp scores from baseline to year 1 for patients in the AMPLE study. []. Copyright © 2013 by the American College of Rheumatology.
AMPLE is an ongoing study comparing s.c. abatacept vs adalimumab in biologic-naïve patients with background MTX. Paired (baseline and year 1) radiographic images were available for 91.1% of patients in the abatacept group and 88.1% of patients in the adalimumab group.

Mean change from baseline DAS28 (CRP) score in patients in the ACCOMPANY study (A) over 4 months for the ITT population [n = 49 in the s.c. abatacept monotherapy group, n = 51 in the s.c. abatacept combination (plus MTX) group] and (B) over 18 months for patients who entered the LTE (n = 43 in the monotherapy group, n = 47 in the combination group) (as-observed analysis). []. Copyright © 2012 by the American College of Rheumatology.
The ACCOMPANY study compared s.c. abatacept with or without MTX in patients with an inadequate response to ≥1 DMARD (MTX-naïve or MTX-IR). Mean (s.d.) baseline DAS28 (CRP) was 5.4 (1.4). Error bars represent 95% CI.

Proportion of s.c. or i.v. abatacept-treated patients in the ACQUIRE study achieving ACR20, -50 or -70 responses (A) over 6 months for the per protocol (PP) population (n = 693 in the s.c. abatacept-treated group, n = 678 in the i.v. abatacept-treated group; non-responder analysis) [] and (B) over 32 months for patients who entered the LTE (all patients received s.c. abatacept + MTX, n = 1372; as-observed analysis) []. Fig. 1b Copyright © 2011 by the American College of Rheumatology. Fig. 1b Copyright © 2012 by the American College of Rheumatology.
The ACQUIRE study compared s.c. vs i.v. abatacept in MTX-IR patients. (A) The estimated difference between the s.c. and i.v. treatment groups for ACR20 at month 6 in the PP population (primary endpoint) was 0.3% (95% CI −4.2, 4.8). (B) Not all patients reached later time points at the time of data analysis. Data on eight patients were excluded from all efficacy analyses due to site non-compliance with study procedures. Error bars represent 95% CI.